Methods for treating spinal muscular atrophy using...

Details Methods for treating spinal muscular atrophy using... Methods for treating spinal muscular atrophy using...

2011-05-03

2011-05-03

Fetterolf, Brandon J (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

3,10-dihydroxy-2-naphthacene carboxamide or derivative doai

C514S231500, C514S616000

Reexamination Certificate

active

07935687

ABSTRACT:
Methods for using tetracycline compounds for the treatment of spinal muscular atrophy are described.

REFERENCES:
patent: 2980584 (1961-04-01), Hammer
patent: 2990331 (1961-06-01), Horst et al.
patent: 3062717 (1962-11-01), Hammer
patent: 3165531 (1965-01-01), Blackwood et al.
patent: 3454697 (1969-07-01), Joyner et al.
patent: 3557280 (1971-01-01), Weber et al.
patent: 3674859 (1972-07-01), Beutel et al.
patent: 3957980 (1976-05-01), Noseworthy
patent: 4018889 (1977-04-01), Armstrong
patent: 4024272 (1977-05-01), Rogalski et al.
patent: 4126680 (1978-11-01), Armstrong
patent: 4806372 (1989-02-01), Strumskis
patent: 5021407 (1991-06-01), Levy
patent: 5258372 (1993-11-01), Levy
patent: 5589470 (1996-12-01), Levy
patent: 5811412 (1998-09-01), Levy
patent: 6256365 (2001-07-01), Lai
patent: 6500812 (2002-12-01), Nelson et al.
patent: 6617318 (2003-09-01), Nelson et al.
patent: 6624168 (2003-09-01), Nelson et al.
patent: 6642270 (2003-11-01), Nelson et al.
patent: 6683068 (2004-01-01), Nelson et al.
patent: 6818634 (2004-11-01), Nelson et al.
patent: 6818635 (2004-11-01), Nelson et al.
patent: 6833365 (2004-12-01), Levy et al.
patent: 6841546 (2005-01-01), Draper et al.
patent: 6846939 (2005-01-01), Nelson et al.
patent: 6849615 (2005-02-01), Nelson et al.
patent: 7001918 (2006-02-01), Huss et al.
patent: 7045507 (2006-05-01), Draper et al.
patent: 7056902 (2006-06-01), Nelson et al.
patent: 7067681 (2006-06-01), Nelson et al.
patent: 7094806 (2006-08-01), Nelson et al.
patent: 7202235 (2007-04-01), Levy et al.
patent: 7208482 (2007-04-01), Garcia-Luzon et al.
patent: 7323492 (2008-01-01), Huss et al.
patent: 7326696 (2008-02-01), Nelson et al.
patent: 7361674 (2008-04-01), Nelson et al.
patent: 7414041 (2008-08-01), Levy
patent: 7521437 (2009-04-01), Nelson et al.
patent: 7553828 (2009-06-01), Nelson et al.
patent: 2003/0069721 (2003-04-01), Podlegar
patent: 2004/0138183 (2004-07-01), Nelson et al.
patent: 2004/0176334 (2004-09-01), Nelson et al.
patent: 2004/0214800 (2004-10-01), Levy et al.
patent: 2004/0214801 (2004-10-01), Nelson et al.
patent: 2004/0242548 (2004-12-01), Draper et al.
patent: 2005/0020545 (2005-01-01), Draper et al.
patent: 2005/0038002 (2005-02-01), Nelson et al.
patent: 2005/0070510 (2005-03-01), Draper et al.
patent: 2005/0143352 (2005-06-01), Nelson et al.
patent: 2005/0250744 (2005-11-01), Levy et al.
patent: 2005/0288262 (2005-12-01), Bandarage et al.
patent: 2006/0003971 (2006-01-01), Nelson
patent: 2006/0084634 (2006-04-01), Huss et al.
patent: 2006/0089336 (2006-04-01), Nelson et al.
patent: 2006/0166944 (2006-07-01), Berniac et al.
patent: 2006/0166945 (2006-07-01), Abato et al.
patent: 2006/0166946 (2006-07-01), Nelson et al.
patent: 2006/0194773 (2006-08-01), Levy et al.
patent: 2006/0281717 (2006-12-01), Berniac et al.
patent: 2006/0287283 (2006-12-01), Amoo et al.
patent: 2007/0072834 (2007-03-01), Nelson et al.
patent: 2007/0093455 (2007-04-01), Abato et al.
patent: 2007/0167415 (2007-07-01), Levy et al.
patent: 2007/0270389 (2007-11-01), Garcia-Luzon et al.
patent: 2008/0015169 (2008-01-01), Nelson et al.
patent: 2008/0070873 (2008-03-01), Alekshun et al.
patent: 2008/0118979 (2008-05-01), Draper et al.
patent: 2008/0167273 (2008-07-01), Nelson et al.
patent: 2008/0287401 (2008-11-01), Johnston et al.
patent: 2008/0300424 (2008-12-01), Nelson et al.
patent: 2008/0306032 (2008-12-01), Nelson et al.
patent: 2008/0312193 (2008-12-01), Assefa et al.
patent: 2009/0054379 (2009-02-01), Huss et al.
patent: 2009/0118269 (2009-05-01), Berniac et al.
patent: 2009/0124583 (2009-05-01), Nelson et al.
patent: 2009/0131696 (2009-05-01), Levy
patent: 2009/0156842 (2009-06-01), Seyedi et al.
patent: 2346535 (1974-04-01), None
patent: WO 03/005971 (2003-01-01), None
patent: WO 2004/038000 (2004-05-01), None
Wirth et. al. (Expert Opinion on Drug Discovery (2007) 2:437-451).
Summer (The Journal of the American Society for Experimental Therapeutics (2006) 3:235-245).
Dorwald F. A. (Side reactions in organic synthesis, 2005, Wiley, VCH, Weinheim, pg. IX of Preface).
Andreassi et. al. (Human Molecular Genetics (2001) 10:2841-2849).
Andreassi et al., “Aclarubicin Treatment Restores SMN Levels to Cells Derived from Type 1 Spinal Muscular Atrophy Patients”,Human Molecular Genetics, 10(24), 2841-2849 (2001).
Berge et al., “Pharmaceutical Salts”,J. Pharm. Sci., 66(1):1-19 (1977).
Chang et al., “Treatment of Spinal Muscular Atrophy by Sodium Butyrate”,PNAS, 98(17), 9808-9813 (2001).
Lim et al., “Modulation of Survival Motor Neuron Pre-mRNA Splicing by Inhibition of Alternative 3′ Splice Site Pairing”,The Journal of Biological Chemistry, 276(48), 45476-45483 (2001).
Miyajima et al., “Identification of a Cis-acting Element for the Regulation of SMN Exon 7 Splicing”, The Journal of Biological Chemistry, 277(26), 23271-23277 (2002).
Nilges et al., “Identification and Characterization of a Tetracycline Semiquinone Formed during the Oxidation of Minocycline”,J. Org. Chem., 56:5623-5630 (1991).
Skordis et al., “Bifunctional Antisense Oligonucleotides Provide a Trans-Acting Splicing Enhancer that Stimulates SMN2 Gene Expression in Patient Fibroblasts”,PNAS, 100(7), 4114-4119 (2003).
Sossi et al., “Premature Termination Mutations in Exon 3 of the SMN1 Gene are Associated with Exon Skipping and a Relatively Mild SMA Phenotype”, European Journal of Human Genetics, 9, 113-120 (2001).
Zhang et al., “An in Vivo Reporter System for Measuring Increased Inclusion of Exon 7 in SMN2 mRNA: Potential Therapy of SMA”,Gene Therapy, 8, 1532-1538 (2001).
Andreassi et al., “Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients”,Human Mol. Genetics, 10(24):2841-2849 (2001).
“Families of spinal muscular atrophy and paratek pharmaceuticals expand drug discovery collaboration for spinal muscular atrophy”, http://www.paratekpharm.com/m—press.html, XP-002492415, 2 pages (2007).
“SMA summit on drug development, session 7: identification of tetracycline compounds that correct defective SMN2 splicing”, http://www.fsma.org/research/clinical/smadrugsummit/smadrugsummitslides/, (2007).
Sumner, C.J. “Therapeutics development for spinal muscular atrophy”,J. Am. Soc. Exp. NeuroTherap., 3(2):235-245 (2006).

Affiliated with

Also associated with

Rating

Methods for treating spinal muscular atrophy using... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for treating spinal muscular atrophy using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating spinal muscular atrophy using... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2694131